A Novel Nanomaterials Approach for Cancer Imaging and Therapeutic Treatment

用于癌症成像和治疗的新型纳米材料方法

基本信息

批准号：
7679581
负责人：
SAYANGDEV NAHA
金额：
$ 15.07万
依托单位：
ADA TECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-01 至 2011-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7679581
关键词：
Address Age Antibodies Apoptosis Area Benign Biodistribution Biomedical Engineering Budgets Cancerous Carbon Carbon Nanotubes Cell Survival Cells Chemicals Clinical Research Complex Comprehensive Cancer Center Contrast Media Data Disease Documentation Drug Delivery Systems Early treatment Effectiveness Elements Ensure Equipment Evaluation Excision Fever Fullerenes Gadolinium Generations Goals Government Heat shock proteins Heating Hydroxyl Radical Image In Vitro Industry Infrared Rays Injury Ions Lanthanoid Series Elements Lead Life Low-Level Laser Therapy Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Marketing Measurement Medical Metabolic Methods Modeling Morphology Nanostructures Nanotechnology Operative Surgical Procedures Outcome Oxygen Paclitaxel Patients Persons Pharmaceutical Preparations Phase Photochemotherapy Principal Investigator Process Production Protocols documentation Public Health Publishing Qualifying Radiation therapy Reactive Oxygen Species Recovery Reporting Research Research Design Research Personnel Research Project Grants Resistance Resolution Seminal Serum Services Shapes Singlet Oxygen Site Small Business Technology Transfer Research Solutions Staging Structure Superoxides Surface Techniques Technology Temperature Testing Therapeutic Therapeutic Agents Thermal Ablation Therapy Thermal Conductivity Time TimeLine Tissues Transmission Electron Microscopy Treatment Efficacy Treatment Protocols United States National Institutes of Health Universities Validation Virginia Western World Work anticancer research base cancer cell cancer imaging cancer therapy cancer type chemical stability chemotherapy commercialization cytotoxicity design effective therapy experience forest gadodiamide hyperthermia treatment improved in vivo in vivo Model interest irradiation minimally invasive nano nanobiotechnology nanomaterials nanometrology nanoprobe nanostructured neoplastic cell next generation novel novel diagnostics novel therapeutics prevent protein expression receptor research and development research study scaffold success targeted delivery toxic metal tumor

项目摘要

DESCRIPTION (provided by applicant): Cancer treatment today is in need of tumor-specific and effective therapies that do not harm the patient and thereby compromise treatment efficacy and prolong recovery time. A multi-modal therapeutic and imaging agent that does not damage healthy living tissue would have tremendous benefit to researchers and victims of this deadly disease. Nanomaterials have the potential to provide the next- generation solutions that are needed, as they offer 1) a unique size range closely matching that of cells (1 to 1,000 nm), 2) a substantial multifunctional capability, and 3) an inherently large surface-to-volume ratio. The proposed research will focus on synthesizing a novel nanomaterial construct and validating its effectiveness. As envisioned, this new construct will offer a multimodal therapeutic advantage by acting simultaneously as an image contrast enhancement agent, a targeted drug-delivery vehicle, a thermal sensitizer, and a generator of singlet oxygen. This research project is specifically designed to address the special NIH STTR Phase I solicitation "Bioengineering Nanotechnology Initiative" (PA-06-008). The expanded project timeline and budget, our strong preliminary data, and the highly experienced team all combine to directly address the goals of this special NIH solicitation. ADA Technologies has assembled a highly qualified R&D team to execute this challenging project. ADA's Principal Investigator is an expert on nanotechnology and nanometrology; the academic STTR partners at Virginia Tech offer substantial experience and equipment for nanomaterials synthesis and hyperthermia treatment; and the Director of the Comprehensive Cancer Center at Wake Forest University offers his services as an expert consultant on cancer research. Given that a primitive version of the proposed nanostructure has already shown efficacy with prostate cancer cells, we will focus on prostate cancer for the initial proof of concept in Phase I. Phase I tasks are designed to validate our ability to create the new nanomaterial structures and to demonstrate the feasibility of nanomaterials synthesis as well as hyperthermia and reactive oxygen treatments. In vitro tissue representative phantoms and preliminary in vivo models will be assessed. Phase I success will set the stage in Phase II for more-complex nanostructure synthesis (including antibody and drug-delivery targeting) and larger- scale in vivo studies. Within Phase III, we will partner will bio-pharma industry to expedite clinical studies and commercialization of this promising bionanotechnology. Ultimately, this nanostructured material will benefit patients, who will receive a more effective and benign treatment protocol; researchers, who will benefit from a highly effective new multi-modal drug agent; and the bio-pharma industry, which will have a more-marketable product for cancer treatment. The potential worldwide market could reach billions of dollars per year through the research's anticipated application to multiple cancer types. PUBLIC HEALTH REELEVANCE: In an age of major medical advances, tumor-specific, non-toxic and effective therapies against cancer cells do not exist as an option for today's 21st-century patients. Next-generation nanomaterials offer new avenues for more efficacious and harmless options for cancer treatment with their ability to be customized with imaging agents, drug molecules, and highly conducting materials for thermal treatment. The proposed, multi-phase STTR project is focused on developing a new, multi-modal nanomaterial for treating numerous cancer types through its enhanced imaging, improved selectivity of targeted treatment, and minimally invasive therapeutic delivery.

描述（由申请人提供）：当今的癌症治疗需要肿瘤特异性有效的疗法，这些疗法不会损害患者，从而损害了治疗疗效并延长了康复时间。一种不会损害健康的活组织的多模式治疗和成像剂对这种致命疾病的研究人员和受害者会带来巨大的好处。纳米材料有可能提供所需的下一代溶液，因为它们提供的1）独特的尺寸范围与单元格（1至1,000 nm），2）具有实质性的多功能能力和3）固有较大的表面与volume比率非常匹配。拟议的研究将着重于综合一种新型的纳米材料结构并验证其有效性。如所设想的那样，这种新构建体将通过同时充当图像对比度增强剂，靶向药物递送车，热敏性敏化剂和单氧氧气的发生器来提供多模式的治疗优势。该研究项目专门旨在解决特殊的NIH STTR阶段I招标“生物工程纳米技术计划”（PA-06-008）。扩展的项目时间表和预算，我们强大的初步数据以及经验丰富的团队都合并了直接解决此特殊NIH招标的目标。 ADA Technologies已组建了一支高素质的研发团队，以执行这个具有挑战性的项目。 ADA的首席研究员是纳米技术和纳米量学的专家；弗吉尼亚理工大学的学术STTR合作伙伴为纳米材料合成和高温治疗提供了丰富的经验和设备；维克森林大学综合癌症中心的主任为癌症研究的专家顾问提供服务。鉴于提出的纳米结构的原始版本已经显示出前列腺癌细胞的功效，我们将专注于前列腺癌，以在第一阶段I的初始概念验证I阶段IS任务旨在验证我们创建新的纳米材料结构的能力，并证明纳米材料的可行性以及纳米材料的可行性以及超高性氧化和反应性氧化氧和反应性的处理。将评估体外组织代表性幻象和体内初步体内模型。第一阶段的成功将在II期中为更复杂的纳米结构合成（包括抗体和药物传递靶向）和体内研究中的大规模研究。在第三阶段中，我们将合作生物制药行业加快这种有希望的Bionanotechnology的临床研究和商业化。最终，这种纳米结构材料将使患者受益，他们将获得更有效，更良性的治疗方案；研究人员将受益于高效的新型多模式药物；以及生物制药行业，该行业将具有更高的癌症治疗产品。通过研究预期对多种癌症类型的应用，全球潜在的市场可能每年达到数十亿美元。公共卫生重新提高：在重大医学进展的时代，针对癌细胞的肿瘤特异性，无毒和有效的疗法不存在作为当今21世纪患者的一种选择。下一代纳米材料为更有效，无害的选择提供了新的途径，可通过成像剂，药物分子和高度传导材料进行热治疗的能力来进行癌症治疗。拟议的多阶段STTR项目的重点是开发一种新的，多模式的纳米材料，用于通过增强的成像，提高目标治疗的选择性以及微创治疗性递送来治疗多种癌症类型。